Drug intelligence / Profile preview

2-pyridone derivative 9b

Development stage
Preclinical
Modality
Small Molecules
01

Overview

2-pyridone derivative 9b is a synthetic small molecule belonging to the class of spiro[indene-2,4′-pyridine] compounds. It acts as a dual inhibitor of human dihydrofolate reductase (h-DHFR) and epidermal growth factor receptor tyrosine kinase (EGFR TK). In preclinical studies, compound 9b demonstrated potent anti-proliferative activity against HepG-2 (hepatocellular carcinoma) and Caco-2 (colorectal carcinoma) cell lines with IC50 values of approximately 6.89 µM and 5.68 µM, respectively. The compound induces apoptosis by halting the cell cycle at the G1/S phase, upregulating BAX, and downregulating Bcl-2 expression in cancer cells. It also exhibits immunomodulatory effects by inhibiting TNF-alpha and IL-6 production more potently than lapatinib in vitro. Mechanistically, it inhibits h-DHFR with an IC50 comparable to methotrexate (~0.19 µM), and EGFR with an IC50 close to that of lapatinib (~0.11 µM). In silico predictions suggest it may inhibit CYP2C9 and CYP3A4 enzymes[1][3][4].

Other names
spiro[indene-2,4′-pyridine] derivative 9b
02

Targets

DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on 2-pyridone derivative 9b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-pyridone derivative 9b.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call